The Pleasant Prairie facility, which spans more than 84,000 square feet, is equipped with state-of-the-art isolator technology and adheres to the highest current good manufacturing practice standards.
The facility will produce a range of injectable medications, providing hospitals and clinicians access to safe, affordable, and critical-need medications.
The rigorous FDA approval process ensures that facilities meet strict safety and quality standards. Nexus Pharmaceuticals, Inc. plans to manufacture a number of NDAs and ANDAs from the Wisconsin-based facility to bring innovative products as well as supply chain durability to the US healthcare system.
The leadership, regulatory, and business functions will remain in the Illinois headquarters facility.
Nexus Pharmaceuticals, Inc., a US-based healthcare company and certified diverse supplier, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive, and more streamlined in practice.
Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they're needed most. For more information about Nexus Pharmaceuticals and its manufacturing facility in Wisconsin.
Upsher-Smith launches Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%
Torrent Pharma starts shipping generic Keveyis (dichlorphenamide), 50mg tablets in US
Upsher-Smith Laboratories introduces Fluphenazine Hydrochloride Tablets
American Regent launches sulphite-free Epinephrine Injection
Teva and Natco Launch Additional Strengths for the Generic Version of Revlimid in the US
Accord Healthcare adds Teriflunomide to oral medications range